|Momenta Pharmaceuticals Inc.|
675 West Kendall Street
United States - Map
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. The companys complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is used to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and M356, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis; M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis; and other biosimilar programs. The companys novel therapeutics programs include Necuparanib, a novel oncology product candidate derived from heparin; Anti-FcRn program for acute and chronic/intermittent therapies in a range of autoantibody driven diseases; SIF3 program, a novel recombinant protein containing three IgG Fc regions to maximize activity; and hsIVIg, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy. It has collaboration and license agreements with Sandoz AG and Mylan Ireland Limited, as well as Baxalta U.S. Inc., Baxalta GmbH, and Baxalta Incorporated. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
|Momenta Pharmaceuticals Inc.’s ISS Governance QuickScore as of May 1, 2016 is 5. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 8; Compensation: 3.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Craig A. Wheeler ,
Chief Exec. Officer, Pres and Exec. Director
|Dr. Ganesh Venkataraman Kaundinya Ph.D.,
Co-Founder, Chief Scientific Officer and Sr. VP of Research
|Mr. Richard P. Shea ,
Chief Financial Officer, Sr. VP and Treasurer
|Mr. Bruce A. Leicher J.D.,
Sr. VP, Gen. Counsel and Corp. Sec.
|Dr. James M. Roach M.D.,
Chief Medical Officer and Sr. VP of Devel.
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|